Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Nalm 1 Human cell line|
|Storage buffer||PBS with 4mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Allophycocyanin (APC) is a stable and highly soluble phycobiliprotein that provides maximal absorbance and fluorescence without susceptibility to internal or external fluorescence quenching, thus providing exceptional quantum yields and molar extinction coefficients.
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lamda light chains. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation. It is expressed in all B cell precursor leukemias.
Analyte Specific Reagent
Human neonatal naive CD4+ T cells have enhanced activation-dependent signaling regulated by the microRNA miR-181a.
MHCD1905 was used in flow cytometry to test if impaired human neonatal CD4(+) T cell immunity is due to reduced signaling by naive CD4(+) T cells following engagement of the αβ-TCR/CD3 complex and CD28.
|Palin AC,Ramachandran V,Acharya S,Lewis DB||Journal of immunology (Baltimore, Md. : 1950) (190:2682)||2013|
In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.
MHCD1905 was used in flow cytometry to examine the impact of Tregs on CAR-modified T cells in the SCID-Beige xenotransplant model.
|Lee JC,Hayman E,Pegram HJ,Santos E,Heller G,Sadelain M,Brentjens R||Cancer research (71:2871)||2011|
AW495831; B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CD19; Differentiation antigen CD19; T-cell surface antigen Leu-12
B4; CD19; CVID3